A Case of Transitional Cell Carcinoma of the Bladder in a Dog Successfully Treated with HER2 and CCR4 Ingibitors

DOI Web Site

Bibliographic Information

Other Title
  • 膀胱移行上皮癌にHER2阻害剤とCCR4阻害剤を用いて良好な経過が得られた犬の1例
  • ボウコウ イコウ ジョウヒガン ニ HER2 ソガイザイ ト CCR4 ソガイザイ オ モチイテ リョウコウ ナ ケイカ ガ エラレタ イヌ ノ 1レイ

Search this article

Abstract

<p>Lapatinib, a molecular targeting inhibitor of human epidermal growth factor 2 (HER2), was used in a dog with transitional epithelial carcinoma located in the bladder triangle, and stability was obtained for 169 days. owing to a growth observed on day 200, mogamulizumab, a humanized monoclonal antibody with regulatory T-cell infiltration inhibitor (CCR4 inhibitor) properties, was added to the lapatinib treatment reginen. This resulted in shrinking of the tumor and partial remission, enabling survival for 334 days. The only side effect of concurrent administration of the two drugs was grade 1 anorexia in the VCOG-CTCAE, which was manageable, and the subject was in very good condition during treatment. Combination therapy including lapatinib and mogamulizumab for transitional epithelial carcinoma of the bladder in dogs can be considered a promising and effective treatment option in the future.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top